TABLE 1.
Bacterial strains and plasmids used in this study
| Strain or plasmid | Relevant genotype or phenotype | Source or reference |
|---|---|---|
| Strains | ||
| E. coli | ||
| DH10B | araD139 Δ(ara, leu)7697 deoR endA1 galK1 galU nupG recA1 rpsL F′-mcrA Δ(mrr-hsdRMS-mrcBC)Φ80dlacZΔM15 ΔlacX74 | Gibco BRL, Paris, France |
| JM109 | endA1 gyrA96 hsdR17 Δ(lac proA) relA recA1 supE44 thi F′ (lacIqlacZΔM15 proAB+ traD36) | 17 |
| In vitro-obtained rifampin-resistant JM109 | Rifampin resistant | 17 |
| P. aeruginosa | ||
| COL-1 | Carbapenem-resistant clinical isolate | This study |
| MKAM 12 | Carbapenem-resistant clinical isolate producing IMP-1 | Y. Arakawa |
| In vitro-obtained ciprofloxacin-resistant P. aeruginosa PU21 | Ciprofloxacin resistant ilv leu streptromycin resistant | 17 |
| Plasmids | ||
| pNOR-2000 | 45-kb natural plasmid that encoded blaVIM-2 | This study |
| pBK-CMV | Neomycin resistant kanamycin resistant | Stratagene, Inc. (Ozyme, Saint-Quentin-en-Yvelines, France) |
| pNOR-2001 | Recombinant plasmid containing a 3,843-bp BamHI insert encoding blaVIM-2 into pBK-CMV | This study |